Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

New, potent, selective, and short-acting peptidic V1a receptor agonists.

Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD.

J Med Chem. 2011 Jul 14;54(13):4388-98. doi: 10.1021/jm200278m. Epub 2011 Jun 20.

PMID:
21688787
2.

Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.

Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):786-96. doi: 10.1124/jpet.111.178848. Epub 2011 Mar 16.

3.

Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.

J Med Chem. 2004 Apr 22;47(9):2375-88.

PMID:
15084136
4.

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.

J Med Chem. 2007 Feb 22;50(4):835-47.

PMID:
17300166
5.
6.

Design and synthesis of potent, highly selective vasopressin hypotensive agonists.

Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.

J Pept Sci. 2006 Sep;12(9):592-604.

PMID:
16625682
7.

Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.

Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.

J Pept Sci. 2006 Mar;12(3):190-8.

PMID:
16130178
8.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
9.

A new series of photoactivatable and iodinatable linear vasopressin antagonists.

Carnazzi E, Aumelas A, Barberis C, Guillon G, Seyer R.

J Med Chem. 1994 Jun 10;37(12):1841-9.

PMID:
8021923
10.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T.

J Med Chem. 2002 Jun 6;45(12):2579-88.

PMID:
12036367
12.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):333-42. doi: 10.1016/j.ejphar.2008.06.010. Epub 2008 Jun 7.

PMID:
18599033
13.

Brain vasopressin and sodium appetite.

Flynn FW, Kirchner TR, Clinton ME.

Am J Physiol Regul Integr Comp Physiol. 2002 Apr;282(4):R1236-44.

PMID:
11893630
14.

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

Manning M, Stoev S, Kolodziejczyk A, Klis WA, Kruszynski M, Misicka A, Olma A, Wo NC, Sawyer WH.

J Med Chem. 1990 Nov;33(11):3079-86.

PMID:
2231609
15.
16.

Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats.

Bucher M, Hobbhahn J, Taeger K, Kurtz A.

Am J Physiol Regul Integr Comp Physiol. 2002 Apr;282(4):R979-84.

PMID:
11893600
17.

Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.

Manning M, Cheng LL, Stoev S, Klis W, Nawrocka E, Olma A, Sawyer WH, Wo NC, Chan WY.

J Pept Sci. 1997 Jan-Feb;3(1):31-46.

PMID:
9230469
18.

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

Manning M, Stoev S, Bankowski K, Misicka A, Lammek B, Wo NC, Sawyer WH.

J Med Chem. 1992 Jan 24;35(2):382-8.

PMID:
1531076
20.

Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties.

Lammek B, Czaja M, Derdowska I, Rekowski P, Trzeciak HI, Sikora P, Szkróbka W, Stojko R, Kupryszewski G.

J Pept Res. 1997 Mar;49(3):261-8.

PMID:
9151259

Supplemental Content

Support Center